| MERGERS, ACQUISITIONS & ASSET SALES |
| Acquiring Company | Target(s) | Deal Summary |
| Meridian Bioscience | Exalenz Bioscience | - Price: $49 million (6.10 Israeli shekels per share)
- Status: Expected to close by end of Q2
- Meridian to add Exalenz’s BreathID Breath Test Systems, a point-of-care urea breath test platform for H. pylori detection
|
| P4 Diagnostix | Strand Diagnostics | - Price: Undisclosed
- Status: Closed
- Assets acquired include Strand’s Know Error system for forensic DNA testing + UroSeq test panel for advanced prostate cancer
- Sale enables Hologic to concentrate breast health and molecular diagnostics core businesses
|
| Quest Diagnostics | Memorial Hermann Health System | - Price: Undisclosed (all cash)
- Status: Expected to close in Q2
- Quest acquires outreach lab division of about 30 patient service centers + 60 in-office lab service sites
- Quest to also provide management services for all 21of Memorial Hermann’s hospital labs + become sole preferred provider of lab services for Memorial Hermann Health Plan
|
| Exact Sciences | Paradigm Diagnostics | - Price: Undisclosed
- Status: Closed
- Exact acquires seller of NGS-based cancer diagnostic test used for therapy selection
|
| Exact Sciences | Viomics | - Price: Undisclosed
- Status: Closed
- Exact acquires molecular diagnostics company specializing in biomarker selection for cancer diagnostics
|
| OncoCyte | Insight Genetics | - Price: $7 million cash + $5 million OncoCyte common shares + 10-year revenue share of up to 10% net collected revenues for current IG pharma service offerings + tiered revenue share percentage of net collected revenues through end of lifecycle of new cancer tests developed using IG’s technology + contingent consideration of up to $6 million cash and/or common shares
- Status: Closed
- OncoCyte acquires IG lung cancer immunotherapy test in development + access to IG’s existing pharma services infrastructure, including a CLIA-certified + CAP-accredited lab + menu of single-gene tests for various biomarkers
|
| Abcam | Applied StemCell | - Price: Undisclosed
- Status: Closed
- Abcam acquires Applied’s gene editing platform and oncology research products, including AccuRef reference materials
|
| Sysmex | Astrego Diagnostics | - Price: Undisclosed
- Status: No closing date announced
- Sysmex to acquire 24.9% stake in company that makes Captiver system for rapid detection of bacterial infection and antibiotic susceptibility in biofluid
|
| Predictive Oncology | Quantitative Medicine | - Price: Undisclosed
- Status: Expected to close by end of H1
- Predictive to couple QM’s Core predictive modeling platform with its own tumor profiling expertise and data to develop precision therapies
|
| STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS |
| Partner 1 | Partner(s) 2+ | Deal Summary |
| BGI Group | Ares Genetics (part of Curetis Group) | - Objective: Make BGI’s COIVD-19 coronavirus detection tests and kits available in Europe
- Dynamic: Ares to launch NGS testing service for virus using BGI reagents
|
| UgenTec | LGC Biosearch Technologies | - Objective: Launch AI-based workflow for COIVD-19 detection
- Dynamic: Research-use-only workflow to be based on UgenTec’s FastFinder PCR diagnostics software platform and Biosearch’s reagents
|
| Thermo Fisher Scientific | NanoPin Technologies | - Objective: Develop liquid chromatography mass spectrometry (LC-MS) workflows for blood-based infectious disease detection
- Dynamic: Leverage use NanoPin’s diagnostic platform and Thermo Fisher’s LC-MS technology to develop sensitive and fast clinical infectious disease assays to determine infection stage and monitor patient treatment response
|
| Thermo Fisher Scientific | Q-linea | - Objective: Commercialize Q-linea’s ASTar automated antibiotic susceptibility testing instrument
- Dynamic: TF gets exclusive rights to offer ASTar instrument in all markets except Sweden
- TF Thermo already offers the Sensititre Complete Automated AST System for determining minimal inhibitory concentration (MIC)
|
| Becton Dickinson | Babson Diagnostics | - Objective: Support small volume blood collection at retail pharmacies
- Dynamic: Combine BD’s capillary blood collection device and Babson’s automated sample handling + analytical technologies to help retail pharmacies offer lab-quality diagnostic testing
|
| Lucid Diagnostics | Fred Hutchinson Cancer Research Center | - Objective: Use Lucid’s EsoCheck Esophageal Cell Collection Device to evaluate Center’s Barrett’s Esophagus (BE) progression biomarkers
- Dynamic: Lucid gets exclusive option to license Center’s BE progression biomarkers for one year after completion of a Phase II study demonstrating their accuracy
|
| Namocell | HepaTx
+
Takara Bio | - Objective: Use Namocell’s Single-Cell Dispenser to perform single-cell isolation on HepaTx’s hepatocyte-like cells (iHeps)
- Dynamic: Will also use Takara’s SMART-seq technology to characterize iHeps
|
| Euformatics | Bio.logis | - Objective: Provide pharmacogenomic information for patients undergoing NGS-based genetic testing
- Dynamic: Integrate Bio.logis’ Genetic Information Management Suite (GIMS) for analyzing genetic test data into Euformatics’ OmnomicsNGS annotation and variant interpretation platform
|
| Advaxis | Personalis | - Objective: Use Personalis’ ImmunoID NeXT Platform for biomarker discovery
- Dynamic: Extension of current collaboration supporting Advaxis’ ongoing Phase I/II program to advance its investigational ADXS-503 antigen delivery construct platform alone and in combination with pembrolizumab for non-small cell lung cancer patients
|
| CosmosID | Bioeostasis | - Objective: Provide standardized, end-to-end services for preclinical development of next-generation microbiome-based health products
- Dynamic: Integrate preclinical development studies from Biomeostasis’ rodent facility with CosmosID’s standardized GLP workflows and strain-level microbiome analysis
|
| ProSciento | Nordic Bioscience | - Objective: Identify translational biomarkers for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
- Dynamic: Use ProSciento’s Nash Pass patient registry and Nordic’s Protein FingerPrint biomarker technology to validate minimally invasive biomarkers for NAFLD and NASH
|
| Predictive Technology Group | Atrin Pharmaceuticals | - Objective: Develop molecular diagnostics to improve selection of cancer patients who will benefit from treatment with DNA damage and response (DDR) inhibitors
- Dynamic: Use Predictive’s sequencing capabilities, GenDB databases and women’s health biobank to study germline mutations in DDR pathways
- Firms also to study common gynecologic disorders, e.g., endometriosis, linked to development of cancers in affected patients
|
| Cellectricon | StressMarq Biosciences | - Objective: Cellectricon to use StressMarq’s reagents for its neurodegenerative research
- Dynamic: StressMarq to give Cellectricon access to its life science reagents including pre-formed fibrils of tau and alpha-synuclein
|
| Biodesix | Streck | - Objective: Incorporate Streck’s blood collection tubes (BCTs) into Biodesix’s sample collection protocols
- Dynamic: Agreement will help Biodesix get FDA approval for lung cancer companion diagnostics using NGS and droplet digital PCR
|
| Sysmex | Riken Innovation | - Objective: Create new diagnostic technologies for diseases that currently don’t have established diagnostic methods
- Dynamic: Sysmex to provide diagnostic R&D expertise and Riken to provide cross-disciplinary research results with resulting technologies and businesses to be rolled out globally
|
| Jackson Laboratory | Shriners Hospitals for Children | - Objective: Research genetic causes of orthopedic disorders in pediatric patients to create new treatments
- Dynamic: Shriners Hospitals to perform NGS testing on DNA samples from families at its hospitals and outpatient locations
- Jackson Lab to analyze data and develop mouse models with same genetic variations as participating patients
|
| DISTRIBUTION, SALES & MARKETING AGREEMENTS |
| Property Owner | Distributor | Deal Summary |
| Molecular Biology Systems | Velocidy Bio | - Products: MBS’ NextGenPCR system
- Territory: US and Canada
- Previously distributed in US by now defunct Canon Biomedical
|
| Sienna Cancer Diagnostics | Immuno Diagnostic | - Products: Sienna’s hTERT (human telomerase reverse transcriptase) test for bladder cancer
- Territory: Finland
- Exclusive
|
| Curetis | Quaphaco | - Products: Curetis’ Unyvero A50 diagnostic system
- Territory: Vietnam
- Exclusive 3-year term which can be renewed in 2-year increments
|
| Inex Innovate | Inalways | - Products: Inex’s OvaCis ovarian cancer test
- Territory: Taiwan
|
| LICENSES |
| Licensor | Licensee | Deal Summary |
| Agilent Technologies | Twist Bioscience | - Limited, non-exclusive license to use trade secrets at center of recently settled lawsuit in which Twist agreed to make one-time $22.5 million payment to Agilent for full relief of claims without admission of liability or wrongdoing
|
| ERS Genomics | Aelian Biotechnology | - Aelian gets right to use ERS Genomics’ CRISPR-Cas9 patent portfolio for its own commercial functional genomic screening platform
|
| NEW CLINICAL STUDIES |
| DX Partner | Other Partner(s) | Description of Study |
Foundation Medicine
+
Chugai Pharmaceutical | National Cancer Center Japan | - Agreement to use FoundationOne Liquid liquid biopsy test in third stage of SCRUM-Japan, the largest cancer genomic screening consortium for late-stage cancer patients in Japan
|
| Natera | Elicio Therapeutics | - Prospective, multicenter Phase I/II clinical trial of Elicio’s immuno-oncology drug ELI-002 in pancreatic cancer patients
|
| SUPPLY, SERVICE & TESTING AGREEMENTS |
| Supplier/Servicer | Client/User | Deal Summary |
| Siemens Healthineers | Quest Diagnostics | - Siemens Healthineers to become Quest’s primary supplier of immunoassay testing products
|
